Cutting-edge Research Unveiled at National Kidney Foundation’s Annual Professional Meeting

Late-breaking presentations shared before thousands at virtual NKF’s 2021 Spring Clinical Meetings

NEW YORKApril 7, 2021 /PRNewswire/ — Today, before the National Kidney Foundation’s 2021 Spring Clinicals Meetings of thousands of kidney health professionals, hundreds of studies from the last year were presented including three studies considered “late-breaking” research papers.

Pubblicità e progresso

The presentations were made at the virtual presentation at the annual Spring Clinical Meetings, which was held virtually for the second year due to COVID-19 restriction. The event is a chance for investigators to share their findings with professionals who attend the conference, which is one of the most respected gatherings of kidney professionals in the United States.

The late-breaking research presented today included a study of RenalytixAI’s new prognostic blood test that will make it easier to diagnosis early kidney disease in patients with type 2 diabetes; a study that demonstrated the safety and tolerability of Metformin as a potential therapeutic intervention in autosomal dominant polycystic kidney disease; and a study that shows that patients on dialysis are more willing than the general population to accept the COVID-19 vaccine.

Clinical Utility of a New Prognostic Test to Predict the Risk of Kidney Function Decline in Diabetic Kidney Disease Patients
Early diagnosis of comorbidities is critical for people with type 2 diabetes to ensure the best outcome and to help slow progression of dangerous kidney disease. The RenalytixAI’s test would lead to earlier diagnosis over the current tests of albuminuria and eGFR and help clinicians to understand the risk of progression and make treatment decisions for patients with early-stage diabetic kidney disease (DKD), the study found.

“In today’s world where comorbidities associated with diabetes are on the rise, if a simple test can enable early intervention to prevent progression of kidney disease, patients and physicians can be more confident about their treatment plans,” said lead investigator Manasi Datar, PhD, Director at Boston Healthcare Associates, who made the presentation. “Since our study found that the results from this test are more important than current tests for physicians to make treatment decisions in their patients, putting this test in the hands of primary care physicians should be priority, as it would positively impact patient management.”

The new blood test detects early-stage DKD before clinical symptoms appear so early intervention can optimize treatment decisions, including medications that can protect patients’ kidneys and help them manage diabetes.

A Randomized Trial of Administration of Metformin in PKD (TAME PKD)
Presented by Ronald D. Perrone, MD, Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine and Nephrologist and Scientific Director of the Clinical and Translational Research Center at Tufts Medical Center, the study is an exciting development for people with ADPKD and the first steps toward a larger clinical trial evaluating efficacy and safety.

“Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease and the 4th leading cause of end-stage kidney disease,” Dr. Perrone said. “Demonstration of the safety and tolerability of metformin in participants with PKD and GFR >50 ml/min is the initial step in further development of this potential treatment for PKD.”

Dr. Perrone noted that the next steps in this research are to look at a larger intervention trial enriched for those at high risk of rapid progress of the disease.

SARS-CoV-2 Vaccine Acceptability in Patients on Dialysis: A Nationwide Survey
The study was presented by investigator Pablo Garcia, MD, Clinical and research fellow in nephrology at Stanford University School of Medicine and American Kidney Fund Clinical Scientist in Nephrology Fellow.

“This is good news for the ability to reach high levels of COVID-19 vaccination in patients on dialysis, because patients on dialysis have higher risk for death or hospitalization from the virus,” Dr. Garcia said.

“The COVID-19 pandemic has presented multiple challenges and has disproportionately affected patients on dialysis,” he said. “At the moment we are lucky to have effective vaccination for COVID-19 — it is the best preventive strategy available in the world. We as healthcare providers should do our best to facilitate information about the vaccines.”

Overall, the research showed that 80 percent of patients on dialysis were willing to get COVID-19 vaccine. Vaccine acceptability was lower among women, younger (18-44 year) age groups, and among Blacks, and Native Americans and Pacific Islanders — up to 30 percent of patients in these groups were vaccine hesitant.

The presentation session was chaired by NKF Chief Medical Officer Joseph Vassalotti, MD.

SOURCE National Kidney Foundation


Con tag:,,


Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.